COPENHAGEN, Denmark, July 07, 2017 -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that we have launched our US eCommerce portal, where the US consumers, can get the trademarked skin care line Vilact® which contains Lactoactive® “the super molecule” that makes a huge different on skin issues as well as smooths, moisturize and beautifying the skin.
With this new eCommerce portal (www.vilacto.com), our products is now available all over the US helping people to get an opportunity to use an alternative to the known products that either doesn’t help or causes side effects.
"This is another important step in our evolution as a public company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive super-molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetics, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc.
Gert Andersen
Phone: +1 646-893-7895
About Vilacto Bio Inc’s new eCommerce portal


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Instagram Outage Disrupts Thousands of U.S. Users
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Washington Post Publisher Will Lewis Steps Down After Layoffs
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



